Vasomotor Symptoms Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The vasomotor symptoms market reached a value of USD 2.7 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 4.9 Billion by 2035, exhibiting a growth rate (CAGR) of 5.39% during 2025-2035.

The vasomotor symptoms market has been comprehensively analyzed in IMARC's new report titled "Vasomotor Symptoms Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Vasomotor symptoms are temperature dysfunctions that occur due to changes in gonadal hormones in females. These symptoms occur due to the constriction or dilation of blood vessels. These symptoms can also be referred to as menopausal symptoms, for which women seek treatment during menopause most often. At around the age of 40, estrogen and progesterone levels start to reduce in females. Therefore, as the females get older, a female may experience vasomotor symptoms. These hormonal fluctuations affect the mechanisms that control blood pressure and temperature control, and females may experience different symptoms. Vasomotor symptoms include hot flashes, night sweats, heart palpitations, and changes in blood pressure. Hormone therapy is the most effective treatment for vasomotor symptoms and other menopausal symptoms. Estrogens are known as potent neuromodulators of several neuronal circuits throughout the central nervous system. Changing estrogen levels during menopause may impact multiple components in maintaining temperature homeostasis. Similarly, for the drug discovery process, understanding the cause of thermoregulatory dysfunction and mechanisms involved in temperature regulation help specialists to introduce effective drugs.

The rising prevalence of menopausal and post-menopausal symptoms owing to the adoption of unhealthy eating habits and sedentary lifestyles is primarily driving the vasomotor symptoms market. In addition to this, the ongoing development of several treatment options that target the brain's thermostat to reduce the incidence of vasomotor symptoms, such as hot flashes, is acting as a significant growth-inducing factor. Furthermore, the emerging popularity of non-hormonal alternatives, such as selective serotonin reuptake inhibitors and selective serotonin-norepinephrine reuptake inhibitors, among patients with a history of breast cancer is also bolstering the market growth. Apart from this, the escalating demand for cognitive behavior therapy for treating complications associated with vasomotor symptoms, such as sleep disturbances and low productivity levels in professional environments, is further creating a positive outlook for the market. This nonpharmacologic treatment aids in modifying dysfunctional emotions, behaviors, and thoughts that enhance personal coping strategies. Additionally, several governing bodies, along with non-governmental organizations (NGOs), are supporting various health education campaigns to address the stigma and associated silence pertaining to symptoms of menopause. This, in turn, is also propelling the adoption of drugs and medications for the treatment of vasomotor symptoms. Apart from this, the introduction of various innovative approaches for treating distressing vasomotor symptoms with the lowest effective dose in the shortest duration is expected to drive the vasomotor symptoms market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the vasomotor symptoms market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for vasomotor symptoms and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vasomotor symptoms market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the vasomotor symptoms market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the vasomotor symptoms market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current vasomotor symptoms marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the vasomotor symptoms market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the vasomotor symptoms across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the vasomotor symptoms across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of vasomotor symptoms across the seven major markets?
• What is the number of prevalent cases (2019-2035) of vasomotor symptoms by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of vasomotor symptoms by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of vasomotor symptoms by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with vasomotor symptoms across the seven major markets?
• What is the size of the vasomotor symptoms patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend vasomotor symptoms of?
• What will be the growth rate of patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for vasomotor symptoms drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the vasomotor symptoms market?
• What are the key regulatory events related to the vasomotor symptoms market?
• What is the structure of clinical trial landscape by status related to the vasomotor symptoms market?
• What is the structure of clinical trial landscape by phase related to the vasomotor symptoms market?
• What is the structure of clinical trial landscape by route of administration related to the vasomotor symptoms market?